Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Liabilities from Discontinued Operations (2020 - 2021)

Agios Pharmaceuticals (AGIO) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 34533000.0 as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 34533000.0, compared with a TTM value of 34533000.0 through Mar 2021, changed N/A, and an annual FY2020 reading of 261269000.0, changed N/A over the prior year.
  • Liabilities from Discontinued Operations was 34533000.0 for Q1 2021 at Agios Pharmaceuticals, down from 261269000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 261269000.0 in Q4 2020 and bottomed at 34533000.0 in Q1 2021.